Dynavax Technologies (DVAX)
(Delayed Data from NSDQ)
$10.43 USD
+0.15 (1.46%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $10.43 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$10.43 USD
+0.15 (1.46%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $10.43 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Zacks News
Dynavax Technologies (DVAX) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Dynavax Technologies (DVAX) closed at $10.52 in the latest trading session, marking a +0.67% move from the prior day.
Bet on These 4 Biotech Stocks With Bright Prospects
by Ekta Bagri
New drug approvals and pipeline development should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position AGEN, CVAC, IMCR and DVAX well amid the volatility.
Atea (AVIR) Dengue Candidate Gets Fast Track Designation
by Zacks Equity Research
Atea Pharmaceuticals (AVIR) obtains Fast Track Designation in the United States for AT-752 for the treatment of dengue virus infection.
Dynavax Technologies (DVAX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Dynavax Technologies (DVAX) closed the most recent trading day at $10.24, moving +1.69% from the previous trading session.
Gilead (GILD) Drugs Get Positive CHMP Opinion for Label Expansion
by Zacks Equity Research
Gilead's (GILD) COVID-19 treatment Veklury and CAR T-cell therapy Yescarta get positive CHMP recommendation for additional indications.
Bristol Myers (BMY) Skin Cancer Drug Gets EC's Approval
by Zacks Equity Research
Bristol Myers (BMY) gets EC approval for the fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor Opdivo (nivolumab and novel LAG-3-blocking antibody relatlimab.
WHO Recommends Gilead's (GILD) Veklury for Severe COVID-19
by Zacks Equity Research
Gilead's (GILD) Veklury is now recommended by the WHO for use in both non-severe COVID-19 patients at the highest risk of hospitalization and those with severe COVID-19.
Bristol Myers' (BMY) Opdivo Meets Main Goal in Melanoma Study
by Zacks Equity Research
Bristol Myers' (BMY) immuno-oncology drug Opdivo demonstrates a statistically significant and clinically meaningful improvement in recurrence-Free survival (RFS) in patients with Stage IIB/C melanoma.
Adverum (ADVM) Doses First Patient in the Mid-Stage wAMD Study
by Zacks Equity Research
Adverum (ADVM) initiates dosing in the phase II LUNA study, currently investigating its lead product candidate ixoberogene soroparvovec for wet age-related macular degeneration.
Is Dynavax Technologies (DVAX) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Gilead (GILD) Up on Settling HIV Drug Suit With Generic Players
by Zacks Equity Research
Gilead (GILD) enters settlement agreements with a few generic manufacturers to resolve the litigation and patent challenges associated with HIV treatments, such as Descovy, Vemlidy and Odefsey.
Edgewise (EWTX) Up 9.37% on Positive Data From BMD Study
by Zacks Equity Research
Edgewise (EWTX) stock gains on upbeat interim results from the ARCH study of its lead candidate EDG-5506 in adults with Becker Muscular Dystrophy (BMD).
Dynavax Technologies (DVAX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Dynavax Technologies (DVAX) closed at $11.78, marking a +1.12% move from the previous day.
Bristol Myers (BMY) Gets FDA Approval for Psoriasis Candidate
by Zacks Equity Research
Bristol Myers (BMY) secures an FDA nod for Sotyktu to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Regeneron (REGN) Up on Higher Dose Eye Drug Studies Success
by Zacks Equity Research
Regeneron (REGN) stock jumps as aflibercept 8 mg with 12- and 16-week dosing regimens in patients with DME and wAMD meet primary goals.
Exelixis (EXEL) Reports Positive Cabometyx Combo Study Results
by Zacks Equity Research
Exelixis (EXEL) announces positive detailed results on the triplet combination study of Cabometyx, Opdivo and Yervoy.
Gilead (GILD) Breast Cancer Drug Trodelvy Improves Survival
by Zacks Equity Research
Gilead (GILD) breast cancer drug Trodelvy demonstrates a statistically significant and clinically meaningful improvement of 3.2 months in overall survival compared to chemotherapy.
Spero (SPRO) Up Following Positive FDA Update for UTI Drug
by Zacks Equity Research
Spero (SPRO) surges on achieving common ground with the FDA on the regulatory path forward for tebipenem HBr.
Gilead (GILD) Announces Positive New Data on Breast Cancer Drug
by Zacks Equity Research
Gilead (GILD) breast cancer drug Trodelvy shows efficacy across HER2-low and IHC0 status in pre-treated metastatic breast cancer patients.
Jounce (JNCE) SELECT Study Fails to Meet Goal, Stock Down
by Zacks Equity Research
Jounce Therapeutics (JNCE) declines as its mid-stage study, SELECT, evaluating vopratelimab in lung cancer patients, fails to meet the primary endpoint.
Novartis (NVS) Chronic Myeloid Leukemia Drug Approved by EC
by Zacks Equity Research
Novartis (NVS) strengthens its oncology portfolio with EC approval for its chronic myeloid leukemia drug, Scemblix.
Gilead (GILD) Outpaces Industry in Six Months: What Lies Ahead?
by Zacks Equity Research
Gilead (GILD) gains on the back of its strong HIV franchise and promising oncology business, which should propel growth further.
Down 21.7% in 4 Weeks, Here's Why Dynavax Technologies (DVAX) Looks Ripe for a Turnaround
by Zacks Equity Research
The heavy selling pressure might have exhausted for Dynavax Technologies (DVAX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Bristol Myers (BMY) Announces Milvexian Phase II Study Results
by Zacks Equity Research
Bristol Myers (BMY) announces AXIOMATIC-SSP study results of milvexian, an investigational oral factor XIa inhibitor, for preventing new symptomatic ischemic stroke or new covert brain infarction.
Incyte (INCY) Gets FDA Nod for Label Expansion of Pemazyre
by Zacks Equity Research
Incyte (INCY) obtains FDA approval for Pemazyre for a second indication - the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement.